Condition (MeSH)
Vitreoretinopathy, Proliferative
ClinicalTrials.gov lists 40 trials for Vitreoretinopathy, Proliferative or a narrower condition beneath it. Aldeyra Therapeutics, Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
40 of the 40 trials are tagged with Vitreoretinopathy, Proliferative itself; the rest are tagged with a narrower condition beneath it.
When did Vitreoretinopathy, Proliferative trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 2 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vitreoretinopathy, Proliferative trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 2/3 | 3 |
| Phase 3 | 7 |
| Phase 4 | 3 |
| Not applicable | 12 |
| Observational | 5 |
How many Vitreoretinopathy, Proliferative trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 17 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vitreoretinopathy, Proliferative trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aldeyra Therapeutics, Inc. | 1 |
Which drugs are being tested for Vitreoretinopathy, Proliferative? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TOPOTECAN | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HD- Methotrexate (MTX) | 5 |
| Control (placebo) group | 2 |
| Triamcinolone Acetonide alone | 2 |
| Bevacizumab 1 | 2 |
| Nepafenac 0.1% eyedrops | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Vitreoretinopathy, Proliferative trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dizziness | 1 | 1 |
Which publications cover Vitreoretinopathy, Proliferative? (53)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial. | Scientific reports | 2024 | Yes |
| Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. | Scientific reports | 2021 | Yes |
| Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. | The Cochrane database of systematic reviews | 2020 | Yes |
| The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. | Cutaneous and ocular toxicology | 2020 | Yes |
| Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. | American journal of ophthalmology | 2018 | Yes |
Showing 5 of 53 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.